BIOGEN INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
BIOGEN INC. (BIIB) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$19.10 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-04-29
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was -$19.10M, a 146.59% decline year-over-year.
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$14.30M, a 119.04% decline year-over-year.
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was -$3.20M.
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-06-30 was -$5.30M, a 117.79% decline year-over-year.
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $18.20M, a 82.23% decline from fiscal 2024.
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $102.40M, a 62.07% decline from fiscal 2023.
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $270.00M, a 2.00% increase from fiscal 2022.
- BIOGEN INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was $264.70M, a 68.16% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | -$19.10M 10-Q · filed 2026-04-29 | -$33.40M derived: sum of 2 quarters · filed 2026-04-29 | -$36.60M derived: sum of 3 quarters · filed 2026-04-29 | -$41.90M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-12-31 | -$14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | -$17.50M derived: sum of 2 quarters · filed 2026-02-06 | -$22.80M derived: sum of 3 quarters · filed 2026-02-06 | $18.20M 10-K · filed 2026-02-06 | ||||
| 2025-09-30 | -$3.20M 10-Q · filed 2025-10-30 | -$8.50M derived: sum of 2 quarters · filed 2025-10-30 | $32.50M 10-Q · filed 2025-10-30 | $107.60M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-06-30 | -$5.30M 10-Q · filed 2025-07-31 | $35.70M 10-Q · filed 2025-07-31 | $110.80M derived: sum of 3 quarters · filed 2026-04-29 | $82.60M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-03-31 | $41.00M 10-Q · filed 2026-04-29 | $116.10M derived: sum of 2 quarters · filed 2026-04-29 | $87.90M derived: sum of 3 quarters · filed 2026-04-29 | $117.70M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $75.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $46.90M derived: sum of 2 quarters · filed 2026-02-06 | $76.70M derived: sum of 3 quarters · filed 2026-02-06 | $102.40M 10-K · filed 2026-02-06 | ||||
| 2024-09-30 | -$28.20M 10-Q · filed 2025-10-30 | $1.60M derived: sum of 2 quarters · filed 2025-10-30 | $27.30M 10-Q · filed 2025-10-30 | $29.00M derived: sum of 4 quarters · filed 2026-02-06 | ||||
| 2024-06-30 | $29.80M 10-Q · filed 2025-07-31 | $55.50M 10-Q · filed 2025-07-31 | $57.20M derived: sum of 3 quarters · filed 2026-02-06 | $354.80M derived: sum of 4 quarters · filed 2026-02-06 | ||||
| 2024-03-31 | $25.70M 10-Q · filed 2025-05-01 | $27.40M derived: sum of 2 quarters · filed 2026-02-06 | $325.00M derived: sum of 3 quarters · filed 2026-02-06 | $219.20M derived: sum of 4 quarters · filed 2026-02-06 | ||||
| 2023-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $299.30M derived: sum of 2 quarters · filed 2026-02-06 | $193.50M derived: sum of 3 quarters · filed 2026-02-06 | $270.00M 10-K · filed 2026-02-06 | ||||
| 2023-09-30 | $297.60M 10-Q · filed 2024-10-30 | $191.80M derived: sum of 2 quarters · filed 2024-10-30 | $268.30M 10-Q · filed 2024-10-30 | $374.90M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | -$105.80M 10-Q · filed 2024-08-01 | -$29.30M 10-Q · filed 2024-08-01 | $77.30M derived: sum of 3 quarters · filed 2025-02-12 | -$32.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | $76.50M 10-Q · filed 2024-04-24 | $183.10M derived: sum of 2 quarters · filed 2025-02-12 | $73.80M derived: sum of 3 quarters · filed 2025-02-12 | $150.30M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $106.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$2.70M derived: sum of 2 quarters · filed 2025-02-12 | $73.80M derived: sum of 3 quarters · filed 2025-02-12 | $264.70M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | -$109.30M 10-Q · filed 2023-11-08 | -$32.80M derived: sum of 2 quarters · filed 2023-11-08 | $158.10M 10-Q · filed 2023-11-08 | $274.30M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-06-30 | $76.50M 10-Q · filed 2023-07-25 | -$76.50M 10-Q · filed 2022-07-20 | $267.40M 10-Q · filed 2023-07-25 | -$267.40M 10-Q · filed 2022-07-20 | $383.60M derived: sum of 3 quarters · filed 2024-02-14 | $810.50M derived: sum of 4 quarters · filed 2024-02-14 | ||
| 2022-03-31 | $190.90M 10-Q · filed 2023-04-25 | -$190.90M 10-Q · filed 2022-05-03 | $307.10M derived: sum of 2 quarters · filed 2024-02-14 | $734.00M derived: sum of 3 quarters · filed 2024-02-14 | $887.90M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2021-12-31 | $116.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $543.10M derived: sum of 2 quarters · filed 2024-02-14 | $697.00M derived: sum of 3 quarters · filed 2024-02-14 | $831.40M 10-K · filed 2024-02-14 | -$831.40M 10-K · filed 2022-02-03 | |||
| 2021-09-30 | $426.90M 10-Q · filed 2022-10-25 | -$426.90M 10-Q · filed 2021-10-20 | $580.80M derived: sum of 2 quarters · filed 2022-10-25 | $715.20M 10-Q · filed 2022-10-25 | -$715.20M 10-Q · filed 2021-10-20 | -$503.00M derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-06-30 | $153.90M 10-Q · filed 2022-07-20 | -$288.40M 10-Q · filed 2022-07-20 | -$929.90M derived: sum of 3 quarters · filed 2023-02-15 | -$1.01B derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-03-31 | -$442.30M 10-Q · filed 2022-05-03 | -$1.08B derived: sum of 2 quarters · filed 2023-02-15 | -$1.17B derived: sum of 3 quarters · filed 2023-02-15 | -$1.06B derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2020-12-31 | -$641.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$723.80M derived: sum of 2 quarters · filed 2023-02-15 | -$620.90M derived: sum of 3 quarters · filed 2023-02-15 | -$681.80M 10-K · filed 2023-02-15 | $681.80M 10-K · filed 2021-02-03 | |||
| 2020-09-30 | -$82.30M 10-Q · filed 2021-10-20 | $20.60M derived: sum of 2 quarters · filed 2021-10-20 | -$40.30M 10-Q · filed 2021-10-20 | -$40.70M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-06-30 | $102.90M 10-Q · filed 2021-07-22 | $42.00M 10-Q · filed 2021-07-22 | $41.60M derived: sum of 3 quarters · filed 2022-02-03 | $32.60M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-03-31 | -$60.90M 10-Q · filed 2021-04-22 | -$61.30M derived: sum of 2 quarters · filed 2022-02-03 | -$70.30M derived: sum of 3 quarters · filed 2022-02-03 | -$201.60M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2019-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | -$9.40M derived: sum of 2 quarters · filed 2022-02-03 | -$140.70M derived: sum of 3 quarters · filed 2022-02-03 | $150.10M 10-K · filed 2022-02-03 | ||||
| 2019-09-30 | -$9.00M 10-Q · filed 2020-10-21 | -$140.30M derived: sum of 2 quarters · filed 2020-10-21 | $150.50M 10-Q · filed 2020-10-21 | $224.10M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-06-30 | -$131.30M 10-Q · filed 2020-07-22 | $159.50M 10-Q · filed 2020-07-22 | $233.10M derived: sum of 3 quarters · filed 2021-02-03 | $374.30M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-03-31 | $376.10M 10-Q · filed 2020-04-23 | $375.00M 10-Q · filed 2019-04-24 | $364.40M derived: sum of 2 quarters · filed 2021-02-03 | $505.60M derived: sum of 3 quarters · filed 2021-02-03 | $511.00M derived: sum of 4 quarters · filed 2021-02-03 | |||
| 2018-12-31 | -$11.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $129.50M derived: sum of 2 quarters · filed 2021-02-03 | $134.90M derived: sum of 3 quarters · filed 2021-02-03 | $128.50M 10-K · filed 2021-02-03 | ||||
| 2018-09-30 | $141.20M 10-Q · filed 2019-10-22 | $146.60M derived: sum of 2 quarters · filed 2019-10-22 | $140.20M 10-Q · filed 2019-10-22 | |||||
| 2018-06-30 | $5.40M 10-Q · filed 2019-07-24 | -$1.00M 10-Q · filed 2019-07-24 | ||||||
| 2018-03-31 | $0.00 10-Q · filed 2019-04-24 | |||||||
| 2017-12-31 | -$19.80M 10-K · filed 2020-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |